Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer

被引:12
|
作者
Schoenherr, Regine M. [1 ]
Kelly-Spratt, Karen S. [1 ]
Lin, ChenWei [1 ]
Whiteaker, Jeffrey R. [1 ]
Liu, Tao [2 ]
Holzman, Ted [1 ]
Coleman, Ilsa [1 ]
Feng, Li-Chia [1 ]
Lorentzen, Travis D. [1 ]
Krasnoselsky, Alexei L. [1 ]
Wang, Pei [1 ]
Liu, Yan [1 ]
Gurley, Kay E. [1 ]
Amon, Lynn M. [1 ]
Schepmoes, Athena A. [2 ]
Moore, Ronald J. [2 ]
Camp, David G., II [2 ]
Chodosh, Lewis A. [3 ]
Smith, Richard D. [2 ]
Nelson, Peter S. [1 ]
McIntosh, Martin W. [1 ]
Kemp, Christopher J. [1 ]
Paulovich, Amanda G. [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[2] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA
[3] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA
关键词
Breast cancer; Her2; Mouse; Proteome; Transcriptome; TANDEM MASS-SPECTROMETRY; CYSTEINYL-PEPTIDE ENRICHMENT; LC-MS; STATISTICAL-MODEL; PERFORMANCE; THROUGHPUT; STANDARDS; PROTEINS; SYSTEM; IDENTIFICATIONS;
D O I
10.1002/prca.201000037
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: We generated extensive transcriptional and proteomic profiles from a Her2-driven mouse model of breast cancer that closely recapitulates human breast cancer. This report makes these data publicly available in raw and processed forms, as a resource to the community. Importantly, we previously made biospecimens from this same mouse model freely available through a sample repository, so researchers can obtain samples to test biological hypotheses without the need of breeding animals and collecting biospecimens. Experimental design: Twelve datasets are available, encompassing 841 LC-MS/MS experiments (plasma and tissues) and 255 microarray analyses of multiple tissues (thymus, spleen, liver, blood cells, and breast). Cases and controls were rigorously paired to avoid bias. Results: In total, 18 880 unique peptides were identified (PeptideProphet peptide error rate <= 1%), with 3884 and 1659 non-redundant protein groups identified in plasma and tissue datasets, respectively. Sixty-one of these protein groups overlapped between cancer plasma and cancer tissue. Conclusions and clinical relevance: These data are of use for advancing our understanding of cancer biology, for software and quality control tool development, investigations of analytical variation in MS/MS data, and selection of proteotypic peptides for multiple reaction monitoring-MS. The availability of these datasets will contribute positively to clinical proteomics.
引用
收藏
页码:179 / 188
页数:10
相关论文
共 50 条
  • [1] Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
    Croci, Stefania
    Nanni, Patrizia
    Palladini, Arianna
    Nicoletti, Giordano
    Grosso, Valentina
    Benegiamo, Giorgia
    Landuzzi, Lorena
    Lamolinara, Alessia
    Ianzano, Marianna L.
    Ranieri, Dario
    Dall'Ora, Massimiliano
    Iezzi, Manuela
    De Giovanni, Carla
    Lollini, Pier-Luigi
    BREAST CANCER RESEARCH, 2015, 17
  • [2] HER2/neu vaccines in breast cancer
    Khoo, Steven
    Ponniah, Sathibalan
    Peoples, George E.
    WOMENS HEALTH, 2006, 2 (02) : 217 - 223
  • [3] Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu
    Fry, Elizabeth A.
    Taneja, Pankaj
    Inoue, Kazushi
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (03) : 495 - 503
  • [4] Classification of HER2/neu Status in Gastric Cancer Using a Breast-Cancer Derived Proteome Classifier
    Balluff, Benjamin
    Elsner, Mareike
    Kowarsch, Andreas
    Rauser, Sandra
    Meding, Stephan
    Schuhmacher, Christoph
    Feith, Marcus
    Herrmann, Ken
    Rocken, Christoph
    Schmid, Roland M.
    Hofler, Heinz
    Walch, Axel
    Ebert, Matthias P.
    JOURNAL OF PROTEOME RESEARCH, 2010, 9 (12) : 6317 - 6322
  • [5] Adjuvant HER2/neu peptide cancer vaccines in breast cancer
    Clifton, Guy T.
    Mittendorf, Elizabeth A.
    Peoples, George E.
    IMMUNOTHERAPY, 2015, 7 (11) : 1159 - 1168
  • [6] Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer
    Osipo, Clodia
    Meeke, Kathleen
    Cheng, Dong
    Weichel, Alyssa
    Bertucci, Anne
    Liu, Hong
    Jordan, V. Craig
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 30 (02) : 509 - 520
  • [7] Influence of Neoadjuvant Chemotherapy on HER2/neu Status in Invasive Breast Cancer
    Li, Peifeng
    Liu, Tantan
    Wang, Yingmei
    Shao, Shuai
    Zhang, Weichen
    Lv, Yang
    Yi, Jun
    Wang, Zhe
    CLINICAL BREAST CANCER, 2013, 13 (01) : 53 - 60
  • [8] HER2/neu in systemic therapy for women with breast cancer: a systematic review
    Bindi Dhesy-Thind
    Kathleen I. Pritchard
    Hans Messersmith
    Frances O’Malley
    Leela Elavathil
    Maureen Trudeau
    Breast Cancer Research and Treatment, 2008, 109 : 209 - 229
  • [9] Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model
    Pakravan, Nafiseh
    Langroudi, Ladan
    Hajimoradi, Monire
    Hassan, Zuhair Mohammad
    CELL STRESS & CHAPERONES, 2010, 15 (06) : 977 - 984
  • [10] The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis
    Bandini, Silvio
    Macagno, Marco
    Hysi, Albana
    Lanzardo, Stefania
    Conti, Laura
    Bello, Amanda
    Riccardo, Federica
    Ruiu, Roberto
    Merighi, Irene Fiore
    Forni, Guido
    Iezzi, Manuela
    Quaglino, Elena
    Cavallo, Federica
    ONCOIMMUNOLOGY, 2016, 5 (12):